11 Commerce Drive
First Floor
Cranford, NJ 07016
United States
908 967 6677
https://citiuspharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 22
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Leonard L. Mazur | Co-Founder, CEO, Chairman & Secretary | 622,53k | N/A | 1945 |
Mr. Myron Z. Holubiak | Co-Founder & Executive Vice Chairman | 589,76k | N/A | 1947 |
Dr. Myron S. Czuczman M.D. | Executive VP & Chief Medical Officer | 525,5k | N/A | 1960 |
Mr. Jaime Bartushak | Chief Business Officer, CFO & Chief Accounting Officer | 485,58k | N/A | 1968 |
Mr. Gary F. Talarico | Executive Vice President of Operations | N/A | N/A | 1955 |
Ms. Ilanit Allen | Vice President of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Dr. Alan Lader Ph.D. | Senior VP and Head of Clinical Operations & Quality Assurance | N/A | N/A | N/A |
Mr. Dhananjay G. Wadekar | Senior Vice President of Business Strategy | N/A | N/A | 1954 |
Mr. Kelly Creighton Ph.D. | Executive Vice President of Chemistry, Manufacturing & Controls | N/A | N/A | N/A |
Mr. Nikolas Burlew | Executive Vice President of Quality Assurance | N/A | N/A | N/A |
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
El ISS Governance QualityScore de Citius Pharmaceuticals, Inc., a día 1 de mayo de 2024, es 6. Las puntuaciones base son Auditoría: 9; Tablero: 8; Derechos de los accionistas: 1; Compensación: 7.